Filana Therapeutics
FLNA
28 hedge funds and large institutions have $9.7M invested in Filana Therapeutics in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.74% less ownership
Funds ownership: 36.68% → 35.94% (-0.74%)
15% less funds holding
Funds holding: 33 → 28 (-5)
56% less capital inflows, than outflows
Capital inflows: $112K | Capital outflows: $254K
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$49.7K |
| 2 |
Panagora Asset Management
Boston,
Massachusetts
|
+$31.4K |
| 3 |
GAMCO Investors
Greenwich,
Connecticut
|
+$25K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.86K |
| 5 |
BlackRock
New York
|
+$1.43K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Gabelli Funds
Rye,
New York
|
-$98K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$50.6K |
| 3 |
Two Sigma Securities
New York
|
-$44K |
| 4 |
First Eagle Investment Management
New York
|
-$25.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$14.9K |
FLNA Hedge Fund Activity: Q3 2017 in Review
28 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q3 2017, worth a combined $9.7M — down 3.3% from $10M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FLNA and 1 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $49.7K. The largest seller was Gabelli Funds, exiting entirely with an estimated $98K sold.
- 28 institutional investors held Filana Therapeutics (FLNA) as of Q3 2017, down from 33 in Q2 2017.
- Funds reported $9.7M of Filana Therapeutics stock for Q3 2017, down 3.3% quarter-over-quarter.
- 1 fund opened new Filana Therapeutics positions in Q3 2017 and 5 closed out, a net change of -4 holders.
- The largest Filana Therapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $49.7K added.
- The largest Filana Therapeutics seller in Q3 2017 was Gabelli Funds, an estimated $98K sold.
Based on aggregated 13F filings for Q3 2017.